Concentrx Pharmaceuticals has raised more than $300,000 of a debt and securities funding out of $1 million sought, according to a regulatory filing. The company sells a medical device for inhaled pharmaceuticals use in respiratory, metabolic, infectious diseases and vaccines.

According to the filing, it raised $307,876 of a targeted $1 million from 11 investors.

The Durham-based company says the device, called the UD-DPI is “available for development with world leading inhaled pharmaceutical products. It adds on its website that it can be used for early stage research and development programs where dry powder formulations are preferred.

Its website lists the device features as:

· Elegant one piece design

· Reduce wasted doses from multi-dose inhalers dispensed in the hospital and institutional setting

· Patent protected in 32 countries

The company disclosed the funding in a filing with the U.S. Securities and Exchange Commission. Here’s the filing:

http://www.sec.gov/Archives/edgar/data/1655145/000165514515000001/xslFormDX01/primary_doc.xml

on the web: http://concentrxpharma.com/